Resectable pancreatic small cell carcinoma

Jordan M. Winter, Amol K. Narang, Aaron S. Mansfield, Joseph M. Herman, John L. Cameron, Dan Laheru, Fred E. Eckhauser, Mathew T. Olson, Ralph H. Hruban, Robert C. Miller, Dana Andersen

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Primary pancreatic small cell carcinoma (SCC) is rare, with just over 30 cases reported in the literature. Only 7 of these patients underwent surgical resection with a median survival of 6 months. Prognosis of SCC is therefore considered to be poor, and the role of adjuvant therapy is uncertain. Here we report two institutions' experience with resectable pancreatic SCC. Six patients with pancreatic SCC treated at the Johns Hopkins Hospital (4 patients) and the Mayo Clinic (2 patients) were identified from prospectively collected pancreatic cancer databases and re-reviewed by pathology. All six patients underwent a pancreaticoduodenectomy. Clinicopathologic data were analyzed, and the literature on pancreatic SCC was reviewed. Median age at diagnosis was 50 years (range 27-60). All six tumors arose in the head of the pancreas. Median tumor size was 3 cm, and all cases had positive lymph nodes except for one patient who only had five nodes sampled. There were no perioperative deaths and three patients had at least one postoperative complication. All six patients received adjuvant therapy, five of whom were given combined modality treatment with radiation, cisplatin, and etoposide. Median survival was 20 months with a range of 9-173 months. The patient who lived for 9 months received chemotherapy only, while the patient who lived for 173 months was given chemoradiation with cisplatin and etoposide and represents the longest reported survival time from pancreatic SCC to date. Pancreatic SCC is an extremely rare form of cancer with a poor prognosis. Patients in this surgical series showed favorable survival rates when compared to prior reports of both resected and unresectable SCC. Cisplatin and etoposide appears to be the preferred chemotherapy regimen, although its efficacy remains uncertain, as does the role of combined modality treatment with radiation.

Original languageEnglish (US)
Pages (from-to)13-17
Number of pages5
JournalRare Tumors
Volume3
Issue number1
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Small Cell Carcinoma
Etoposide
Cisplatin
Survival
Radiation
Drug Therapy
Neoplasms
Pancreaticoduodenectomy
Therapeutics
Pancreatic Neoplasms
Pancreas
Survival Rate
Lymph Nodes
Databases
Pathology

Keywords

  • Carcinoma
  • Pancreas
  • Resectable
  • Small cell

ASJC Scopus subject areas

  • Oncology
  • Histology

Cite this

Winter, J. M., Narang, A. K., Mansfield, A. S., Herman, J. M., Cameron, J. L., Laheru, D., ... Andersen, D. (2011). Resectable pancreatic small cell carcinoma. Rare Tumors, 3(1), 13-17. https://doi.org/10.4081/rt.2011.e5

Resectable pancreatic small cell carcinoma. / Winter, Jordan M.; Narang, Amol K.; Mansfield, Aaron S.; Herman, Joseph M.; Cameron, John L.; Laheru, Dan; Eckhauser, Fred E.; Olson, Mathew T.; Hruban, Ralph H.; Miller, Robert C.; Andersen, Dana.

In: Rare Tumors, Vol. 3, No. 1, 2011, p. 13-17.

Research output: Contribution to journalArticle

Winter, JM, Narang, AK, Mansfield, AS, Herman, JM, Cameron, JL, Laheru, D, Eckhauser, FE, Olson, MT, Hruban, RH, Miller, RC & Andersen, D 2011, 'Resectable pancreatic small cell carcinoma', Rare Tumors, vol. 3, no. 1, pp. 13-17. https://doi.org/10.4081/rt.2011.e5
Winter JM, Narang AK, Mansfield AS, Herman JM, Cameron JL, Laheru D et al. Resectable pancreatic small cell carcinoma. Rare Tumors. 2011;3(1):13-17. https://doi.org/10.4081/rt.2011.e5
Winter, Jordan M. ; Narang, Amol K. ; Mansfield, Aaron S. ; Herman, Joseph M. ; Cameron, John L. ; Laheru, Dan ; Eckhauser, Fred E. ; Olson, Mathew T. ; Hruban, Ralph H. ; Miller, Robert C. ; Andersen, Dana. / Resectable pancreatic small cell carcinoma. In: Rare Tumors. 2011 ; Vol. 3, No. 1. pp. 13-17.
@article{ba8982e6537f4b08922f40ad9e6c5e35,
title = "Resectable pancreatic small cell carcinoma",
abstract = "Primary pancreatic small cell carcinoma (SCC) is rare, with just over 30 cases reported in the literature. Only 7 of these patients underwent surgical resection with a median survival of 6 months. Prognosis of SCC is therefore considered to be poor, and the role of adjuvant therapy is uncertain. Here we report two institutions' experience with resectable pancreatic SCC. Six patients with pancreatic SCC treated at the Johns Hopkins Hospital (4 patients) and the Mayo Clinic (2 patients) were identified from prospectively collected pancreatic cancer databases and re-reviewed by pathology. All six patients underwent a pancreaticoduodenectomy. Clinicopathologic data were analyzed, and the literature on pancreatic SCC was reviewed. Median age at diagnosis was 50 years (range 27-60). All six tumors arose in the head of the pancreas. Median tumor size was 3 cm, and all cases had positive lymph nodes except for one patient who only had five nodes sampled. There were no perioperative deaths and three patients had at least one postoperative complication. All six patients received adjuvant therapy, five of whom were given combined modality treatment with radiation, cisplatin, and etoposide. Median survival was 20 months with a range of 9-173 months. The patient who lived for 9 months received chemotherapy only, while the patient who lived for 173 months was given chemoradiation with cisplatin and etoposide and represents the longest reported survival time from pancreatic SCC to date. Pancreatic SCC is an extremely rare form of cancer with a poor prognosis. Patients in this surgical series showed favorable survival rates when compared to prior reports of both resected and unresectable SCC. Cisplatin and etoposide appears to be the preferred chemotherapy regimen, although its efficacy remains uncertain, as does the role of combined modality treatment with radiation.",
keywords = "Carcinoma, Pancreas, Resectable, Small cell",
author = "Winter, {Jordan M.} and Narang, {Amol K.} and Mansfield, {Aaron S.} and Herman, {Joseph M.} and Cameron, {John L.} and Dan Laheru and Eckhauser, {Fred E.} and Olson, {Mathew T.} and Hruban, {Ralph H.} and Miller, {Robert C.} and Dana Andersen",
year = "2011",
doi = "10.4081/rt.2011.e5",
language = "English (US)",
volume = "3",
pages = "13--17",
journal = "Rare Tumors",
issn = "2036-3605",
publisher = "PagePress",
number = "1",

}

TY - JOUR

T1 - Resectable pancreatic small cell carcinoma

AU - Winter, Jordan M.

AU - Narang, Amol K.

AU - Mansfield, Aaron S.

AU - Herman, Joseph M.

AU - Cameron, John L.

AU - Laheru, Dan

AU - Eckhauser, Fred E.

AU - Olson, Mathew T.

AU - Hruban, Ralph H.

AU - Miller, Robert C.

AU - Andersen, Dana

PY - 2011

Y1 - 2011

N2 - Primary pancreatic small cell carcinoma (SCC) is rare, with just over 30 cases reported in the literature. Only 7 of these patients underwent surgical resection with a median survival of 6 months. Prognosis of SCC is therefore considered to be poor, and the role of adjuvant therapy is uncertain. Here we report two institutions' experience with resectable pancreatic SCC. Six patients with pancreatic SCC treated at the Johns Hopkins Hospital (4 patients) and the Mayo Clinic (2 patients) were identified from prospectively collected pancreatic cancer databases and re-reviewed by pathology. All six patients underwent a pancreaticoduodenectomy. Clinicopathologic data were analyzed, and the literature on pancreatic SCC was reviewed. Median age at diagnosis was 50 years (range 27-60). All six tumors arose in the head of the pancreas. Median tumor size was 3 cm, and all cases had positive lymph nodes except for one patient who only had five nodes sampled. There were no perioperative deaths and three patients had at least one postoperative complication. All six patients received adjuvant therapy, five of whom were given combined modality treatment with radiation, cisplatin, and etoposide. Median survival was 20 months with a range of 9-173 months. The patient who lived for 9 months received chemotherapy only, while the patient who lived for 173 months was given chemoradiation with cisplatin and etoposide and represents the longest reported survival time from pancreatic SCC to date. Pancreatic SCC is an extremely rare form of cancer with a poor prognosis. Patients in this surgical series showed favorable survival rates when compared to prior reports of both resected and unresectable SCC. Cisplatin and etoposide appears to be the preferred chemotherapy regimen, although its efficacy remains uncertain, as does the role of combined modality treatment with radiation.

AB - Primary pancreatic small cell carcinoma (SCC) is rare, with just over 30 cases reported in the literature. Only 7 of these patients underwent surgical resection with a median survival of 6 months. Prognosis of SCC is therefore considered to be poor, and the role of adjuvant therapy is uncertain. Here we report two institutions' experience with resectable pancreatic SCC. Six patients with pancreatic SCC treated at the Johns Hopkins Hospital (4 patients) and the Mayo Clinic (2 patients) were identified from prospectively collected pancreatic cancer databases and re-reviewed by pathology. All six patients underwent a pancreaticoduodenectomy. Clinicopathologic data were analyzed, and the literature on pancreatic SCC was reviewed. Median age at diagnosis was 50 years (range 27-60). All six tumors arose in the head of the pancreas. Median tumor size was 3 cm, and all cases had positive lymph nodes except for one patient who only had five nodes sampled. There were no perioperative deaths and three patients had at least one postoperative complication. All six patients received adjuvant therapy, five of whom were given combined modality treatment with radiation, cisplatin, and etoposide. Median survival was 20 months with a range of 9-173 months. The patient who lived for 9 months received chemotherapy only, while the patient who lived for 173 months was given chemoradiation with cisplatin and etoposide and represents the longest reported survival time from pancreatic SCC to date. Pancreatic SCC is an extremely rare form of cancer with a poor prognosis. Patients in this surgical series showed favorable survival rates when compared to prior reports of both resected and unresectable SCC. Cisplatin and etoposide appears to be the preferred chemotherapy regimen, although its efficacy remains uncertain, as does the role of combined modality treatment with radiation.

KW - Carcinoma

KW - Pancreas

KW - Resectable

KW - Small cell

UR - http://www.scopus.com/inward/record.url?scp=79952415112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952415112&partnerID=8YFLogxK

U2 - 10.4081/rt.2011.e5

DO - 10.4081/rt.2011.e5

M3 - Article

C2 - 21464878

AN - SCOPUS:79952415112

VL - 3

SP - 13

EP - 17

JO - Rare Tumors

JF - Rare Tumors

SN - 2036-3605

IS - 1

ER -